Literature DB >> 29862951

Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?

I Bouzouita1, A M Cabibbe2, A Trovato2, H Draoui3, A Ghariani4, B Midouni1, L Essalah3, E Mehiri4, D M Cirillo2, L Slim-Saidi4.   

Abstract

SETTING: Phenotypic tests used to detect pyrazinamide (PZA) resistance are slow and have a high rate of false resistance.
OBJECTIVE: To evaluate the accuracy of pncA sequencing for the detection of PZA resistance in Mycobacterium tuberculosis strains isolated in Tunisia.
DESIGN: A total of 82 isolates, 41 resistant and 41 susceptible to PZA on BACTEC™ MGIT™ 960, were sequenced for pncA. Whole genome sequencing was performed for strains that were phenotypically resistant and had wild-type pncA in addition to MGIT retesting with a modified protocol.
RESULTS: Twenty-three strains resistant to PZA with negative pyrazinamidase (PZase) activity harboured a mutation in the promoter or coding region of pncA. However, 18 strains resistant to PZA did not present any mutation. Repeat MGIT 960 showed that 16 of 18 M. tuberculosis isolates were falsely resistant to PZA. Compared with MGIT, PZase activity assay and pncA sequencing both presented a sensitivity of 92.0% (95%CI 73.9-99.0) and a specificity of respectively 96.5% (positive predictive value [PPV] 92.0%, negative predictive value [NPV] 96.5%) and 100.0% (PPV 100.0%, NPV 96.6%).
CONCLUSION: The standard MGIT assay showed a high rate of false resistance to PZA, and the PZase activity assay is slow. pncA sequencing could therefore represent a rapid, accurate, alternative test to detect PZA resistance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29862951     DOI: 10.5588/ijtld.17.0715

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

1.  Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.

Authors:  Clarisse A Tsang; Neha Shah; Lori R Armstrong; Suzanne M Marks
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

2.  Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion.

Authors:  Eleanor S Click; Ekaterina V Kurbatova; Heather Alexander; Tracy L Dalton; Michael P Chen; James E Posey; Julia Ershova; J Peter Cegielski
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

3.  Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Tomotada Iwamoto; Yoshiro Murase; Shiomi Yoshida; Akio Aono; Makoto Kuroda; Tsuyoshi Sekizuka; Akifumi Yamashita; Kengo Kato; Takemasa Takii; Kentaro Arikawa; Seiya Kato; Satoshi Mitarai
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

4.  Evaluation of PCR pncA-restriction fragment length polymorphism and PCR amplification of genomic regions of difference for the identification of M. bovis strains in lymph nodes cultures.

Authors:  Imen Bouzouita; Henda Draoui; Samia Mahdhi; Leila Essalah; Leila Slim Saidi
Journal:  Afr Health Sci       Date:  2021-09       Impact factor: 0.927

Review 5.  Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.

Authors:  Navisha Dookie; Azraa Khan; Nesri Padayatchi; Kogieleum Naidoo
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

6.  Performance of Wayne assay for detection of pyrazinamide resistance in Mycobacterium tuberculosis: a meta-analysis study.

Authors:  M J Nasiri; F Fardsanei; M Arshadi; B Deihim; Farima Khalili; M Dadashi; M Goudarzi; M Mirsaeidi
Journal:  New Microbes New Infect       Date:  2021-05-05

7.  High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.

Authors:  Resty Naluyange; Gerald Mboowa; Kevin Komakech; Derrick Semugenze; David Patrick Kateete; Willy Ssengooba
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.